Kaitai Capital

Kaitai Capital is a Hangzhou-based early-stage investor specializing in cutting-edge biotechnology therapeutics and novel drug delivery mechanisms, with broader pharma and biotech exposure at seed and Series A. The firm sits within the broader Yangtze River Delta life sciences ecosystem, which has emerged as a meaningful complement to Shanghai’s biotech cluster. The thesis emphasis on therapeutics and delivery suggests interest in platform companies whose science can apply across multiple disease indications rather than single-asset bets. Limited public information about named partners, fund vintages, and specific portfolio positions is available in English-language sources, so founders should plan to engage directly to validate scope.

Check sizes range from 1 million to 5 million dollars at seed and Series A, sized to underwrite early validation work, IND-enabling studies, and initial team build-out for biotech companies. Geography centers on China with Hangzhou as the base, and the firm is well-positioned for founders building within the Chinese biotech corridor. Capital-intensive biotech companies should anticipate that Kaitai is most likely a co-investor or smaller lead at this stage rather than a sole financier through to clinical proof.

The approach is best suited to scientist-founders building platform therapeutics or drug delivery technologies with a credible path through Chinese regulatory and clinical systems. Founders expecting a Western-style governance template or rapid international syndication should calibrate accordingly. Initial conversations should focus on the company’s therapeutic platform thesis, IND timeline, and what specific operational support Kaitai offers, particularly around CRO relationships, regulatory consulting, and follow-on syndicate building for the Series B and beyond.